Main Menu

Dr Julia Murray

Group Leader

The alt text
Dr Julia Murray is a clinical researcher evaluating new radiotherapy techniques and devices in prostate cancer. She is involved in several clinical prostate cancer trials and her research goals are to optimise radiotherapy strategies to improve patient outcomes. ORCID 0000-0003-3550-6178


Dr Julia Murray was appointed as a Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust in 2017, specialising in radiotherapy and systemic therapies for prostate cancer.

She graduated from Imperial College London in 2004 and completed her general medical and clinical oncology training in London. In 2013, she was awarded a Cancer Research UK PhD Fellowship at The Institute of Cancer Research and The Royal Marsden Hospital investigating image guided prostate radiotherapy and the relationship of radiation dose and toxicity. She received her PhD in 2017.

Her current research interests focus on evaluating advanced radiotherapy technology to improve treatment accuracy and patient outcomes. Dr Murray is currently leading a trial evaluating a rectal obturator in post-operative prostate radiotherapy (the POPS trial). She has recently developed a randomised trial looking at the role of para-aortic radiotherapy in prostate cancer patients whose cancer has spread to the lymph nodes within the pelvis and/or para-aortic region. 

She is a Trustee of the British Uro-oncology Group (BUG).